Identification of a Prognostic Risk Signature of Kidney Renal Clear Cell Carcinoma Based on Regulating the Immune Response Pathway Exploration. (30th December 2020)

• Record Type: Journal Article
• Authors: Wu, Guangzhen; Xu, Yingkun; Han, Chenglin; Wang, Zilong; Li, Jiayi; Wang, Qifei; Che, Xiangyu
• Other Names: Zhang Yue Academic Editor.
• Is Part Of: Journal of oncology. Volume 2020(2020)
• Publication Date: 2020-12-30
• Subjects: Oncology -- Research -- Periodicals; Tumors -- Periodicals; Neoplasms; Oncology -- Research; Tumors; Periodicals; Periodicals; 616.994
• DOI: 10.1155/2020/6657013
• Languages: English
• ISSNs: 1687-8450

Abstract

Abstract : Purpose . To construct a survival model for predicting the prognosis of patients with kidney renal clear cell carcinoma (KIRC) based on gene expression related to immune response regulation. Materials and Methods . KIRC mRNA sequencing data and patient clinical data were downloaded from the TCGA database. The pathways and genes involved in the regulation of the immune response were identified from the GSEA database. A single factor Cox analysis was used to determine the association of mRNA in relation to patient prognosis P < 0.05 . The prognostic risk model was further established using the LASSO regression curve. The survival prognosis model was constructed, and the sensitivity and specificity of the model were evaluated using the ROC curve. Results . Compared with normal kidney tissues, there were 28 dysregulated mRNA expressions in KIRC tissues P < 0.05 . Univariate Cox regression analysis revealed that 12 mRNAs were related to the prognosis of patients with renal cell carcinoma. The LASSO regression curve drew a risk signature consisting of six genes: TRAF6, FYN, IKBKG, LAT2, C2, IL4, EREG, TRAF2, and IL12A. The five-year ROC area analysis (AUC) showed that the model has good sensitivity and specificity (AUC >0.712). Conclusion . We constructed a risk prediction model based on the regulated immune response-related genes, which can effectively predict the survival of patients with KIRC.